期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 60, 期 3, 页码 496-497出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2008.09.007
关键词
-
类别
Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as histiocytoid Sweet syndrome. (J Am Acad Dermatol 2009;60:496-7.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据